In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

The best metric is not weight, but a particularly toxic kind of fat.

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...